0000914475-24-000138.txt : 20240521 0000914475-24-000138.hdr.sgml : 20240521 20240521173530 ACCESSION NUMBER: 0000914475-24-000138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240517 FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sharp Shalini CENTRAL INDEX KEY: 0001377202 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24970909 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1716327316.xml FORM 4 X0508 4 2024-05-17 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001377202 Sharp Shalini 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 0 0 0 1 Common Stock 2024-05-17 4 M 0 2100 0 A 2100 D Common Stock 2024-05-17 4 S 0 1106 141.9018 D 994 D Restricted Stock Unit 2024-05-17 4 M 0 2100 0 D Common Stock 2100 0 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. /s/ Darin Lippoldt, Attorney-in-Fact 2024-05-21